The aim of the Anti-Interleukin-1 in Diabetes Action trial (AIDA) study is to test the feasibility, safety/tolerability and potential efficacy of anti-IL-1 therapy in maintaining or enhancing beta-cell function in people with new-onset Type 1 diabetes.

The study employs a randomized, placebo-controlled, double-masked, parallel-group, multi-centre design. Participating clinical centres are located in 11 countries throughout Europe.

Learn More >

Supported by:

The active drug (Kineret®) and the non active “dummy” drug are provided by Amgen. Amgen does not provide funding for the conduct of the trial or to the researchers.